- Home
- CHRS vs EGAN Comparison
CHRS vs EGAN Comparison
Compare CHRS & EGAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EGAN
- Stock Information
- Founded
- CHRS 2010
- EGAN 1997
- Country
- CHRS United States
- EGAN United States
- Employees
- CHRS 235
- EGAN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EGAN Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- EGAN Technology
- Exchange
- CHRS Nasdaq
- EGAN Nasdaq
- Market Cap
- CHRS 134.4M
- EGAN 186.5M
- IPO Year
- CHRS 2014
- EGAN 1999
- Fundamental
- Price
- CHRS $1.22
- EGAN $6.43
- Analyst Decision
- CHRS Strong Buy
- EGAN Buy
- Analyst Count
- CHRS 4
- EGAN 2
- Target Price
- CHRS $5.38
- EGAN $9.50
- AVG Volume (30 Days)
- CHRS 2.4M
- EGAN 103.9K
- Earning Date
- CHRS 03-12-2025
- EGAN 02-14-2025
- Dividend Yield
- CHRS N/A
- EGAN N/A
- EPS Growth
- CHRS N/A
- EGAN 37.92
- EPS
- CHRS N/A
- EGAN 0.19
- Revenue
- CHRS $304,340,000.00
- EGAN $90,426,000.00
- Revenue This Year
- CHRS $2.47
- EGAN $1.52
- Revenue Next Year
- CHRS N/A
- EGAN $10.05
- P/E Ratio
- CHRS N/A
- EGAN $33.12
- Revenue Growth
- CHRS 44.19
- EGAN N/A
- 52 Week Low
- CHRS $0.66
- EGAN $4.71
- 52 Week High
- CHRS $2.87
- EGAN $7.83
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- EGAN 50.41
- Support Level
- CHRS $1.03
- EGAN $5.81
- Resistance Level
- CHRS $1.23
- EGAN $6.46
- Average True Range (ATR)
- CHRS 0.13
- EGAN 0.25
- MACD
- CHRS -0.02
- EGAN -0.06
- Stochastic Oscillator
- CHRS 38.89
- EGAN 53.33
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About EGAN eGain Corporation
eGain Corp automates customer engagement with an innovative Software as a service (SaaS) platform, powered by deep digital, Artificial intelligence (AI), and knowledge capabilities. It operates in the United States, the United Kingdom, and India. The company derives maximum of its revenues from North America. It provides its products to industries such as financial services, telecommunications, retail, government, healthcare, and utilities.